Monitoring molecular response in chronic myeloid leukemia
Authors:
Open Access
Abstract
Before the advent of tyrosine kinase inhibitor (TKI) therapy, the evaluation of hematologic and cytogenetic responses was sufficient to gauge treatment efficacy in patients with chronic myeloid leukemia. However, with more potent TKI therapies, the majority of patients achieve complete cytogenetic response. Furthermore, deeper molecular responses are now commonly achieved, necessitating a reliance on molecular monitoring to assess residual leukemic disease. The prognostic significance between molecular responses and duration of complete cytogenetic response, progression‐free survival, and event‐free survival is described herein. A discussion of the concept of complete molecular response is also provided, and the potential for imatinib treatment discontinuation is evaluated. The implications of rising BCR‐ABL1 transcript levels and caveats of molecular monitoring are also described. Cancer 2011. © 2010 American Cancer Society.Keywords
This publication has 41 references indexed in Scilit:
- Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinibHaematologica, 2010
- Significance of Increasing Levels of Minimal Residual Disease in Patients With Philadelphia Chromosome–Positive Chronic Myelogenous Leukemia in Complete Cytogenetic ResponseJournal of Clinical Oncology, 2009
- European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poorBlood, 2008
- Cytogenetic and molecular responses and outcome in chronic myelogenous leukemiaCancer, 2008
- Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 yearsBlood, 2006
- Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABLLeukemia, 2006
- Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib MesylateClinical Cancer Research, 2005
- Discontinuation of imatinib therapy after achieving a molecular responseBlood, 2004
- Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remissionLeukemia, 2003
- Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid LeukemiaNew England Journal of Medicine, 2003